National Cancer Institute (NCI): all 3,554 studies

Page 7 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004TerminatedNCT03050814Phase 2Results posted
• T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing LymphomasCompletedNCT03049449Phase 1Results posted
• Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsActive, not recruitingNCT03047213Phase 2Results posted
• Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar RhabdomyosarcomaTerminatedNCT03041701Phase 1/2Results posted
• Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R MutationsCompletedNCT03040986Phase 2Results posted
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasActive, not recruitingNCT03038672Phase 2Results posted
• Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant RecipientsActive, not recruitingNCT03036930Phase 2Results posted
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
• Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 1Results posted
• Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and LymphomasCompletedNCT03030417Phase 1Results posted
• Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention MessagingCompletedNCT03027466Not applicableResults posted
• Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompletedNCT03027388Phase 2Results posted
• Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)TerminatedNCT03018288Phase 2Results posted
• Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial CancerCompletedNCT03018249Early Phase 1Results posted
• Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryCompletedNCT03008278Phase 1/2Results posted
• CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerTerminatedNCT03002623Phase 2Results posted
• Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesActive, not recruitingNCT02993146Phase 1Results posted
• Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02974621Phase 2Results posted
• Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesActive, not recruitingNCT02971501Phase 2Results posted
• Simvastatin in Preventing Liver Cancer in Patients With Liver CirrhosisCompletedNCT02968810Phase 2Results posted
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT02965716Phase 2Results posted
• Aspirin in Preventing Colorectal Cancer in Patients With Colorectal AdenomaActive, not recruitingNCT02965703Phase 2Results posted
• Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerCompletedNCT02961374Phase 2Results posted
• Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerTerminatedNCT02948426Phase 1Results posted
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and GlioblastomaTerminatedNCT02942264Phase 1/2Results posted
• Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating AgentsCompletedNCT02936752Phase 1Results posted
• PROSTVAC in Combination With Nivolumab in Men With Prostate CancerCompletedNCT02933255Phase 1/2Results posted
• Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical CancerCompletedNCT02921269Phase 2Results posted
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerCompletedNCT02921256Phase 2Results posted
• ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive TreatmentTerminatedNCT02917629Phase 2Results posted
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairActive, not recruitingNCT02912559Phase 3Results posted
• Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell LymphomaActive, not recruitingNCT02911142Phase 1/2Results posted
• Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung CancerTerminatedNCT02899728Phase 2Results posted
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results posted
• Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedNCT02893930Phase 2Results posted
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerActive, not recruitingNCT02893917Phase 2Results posted
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerCompletedNCT02890355Phase 2Results posted
• Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaActive, not recruitingNCT02890329Phase 1Results posted
• Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerActive, not recruitingNCT02888743Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerActive, not recruitingNCT02883062Phase 2Results posted
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsCompletedNCT02883049Phase 3Results posted
• Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaActive, not recruitingNCT02879695Phase 1Results posted
• Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast CancerTerminatedNCT02876640Phase 1Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Avelumab for People With Recurrent Respiratory PapillomatosisCompletedNCT02859454Phase 2Results posted
• Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesTerminatedNCT02859415Phase 1/2Results posted
• E7 TCR T Cells for Human Papillomavirus-Associated CancersCompletedNCT02858310Phase 1/2Results posted
• Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerCompletedNCT02844816Phase 2Results posted
• Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous NeurofibromaCompletedNCT02839720Phase 2Results posted
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02839707Phase 2/3Results posted
• Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaTerminatedNCT02839681Phase 2Results posted
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene RearrangementCompletedNCT02828358Phase 2Results posted
• A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompletedNCT02810418Phase 1/2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant MesotheliomaCompletedNCT02798536Phase 1Results posted
• Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompletedNCT02788201Phase 2Results posted
• Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal MetaplasiaActive, not recruitingNCT02782949Phase 2Results posted
• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsCompletedNCT02780804Phase 1Results posted
• Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by SurgeryActive, not recruitingNCT02775851Phase 2Results posted
• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT02769962Phase 1/2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With OsimertinibCompletedNCT02759835Phase 2Results posted
• Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02759731Phase 1/2Results posted
• Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic PancreatitisCompletedNCT02743364Phase 2Results posted
• Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid TumorsCompletedNCT02723864Phase 1Results posted
• Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 1Results posted
• T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesCompletedNCT02659943Phase 1Results posted
• Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate CancerCompletedNCT02649855Phase 2Results posted
• Prostvac in Patients With Biochemically Recurrent Prostate CancerCompletedNCT02649439Phase 2Results posted
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02642042Phase 2Results posted
• Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast CancerCompletedNCT02636582Phase 2Results posted
• Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaCompletedNCT02631746Phase 2Results posted
• Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02627443Phase 1Results posted
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaTerminatedNCT02601209Phase 1/2Results posted
• Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerCompletedNCT02598557Phase 2Results posted
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedNCT02595905Phase 2Results posted
• Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02595892Phase 2Results posted
• Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal CancerActive, not recruitingNCT02595879Phase 1Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsActive, not recruitingNCT02589522Phase 1Results posted
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous MelanomaCompletedNCT02581930Phase 2Results posted
• Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant LesionActive, not recruitingNCT02581137Phase 2Results posted
• Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCLTerminatedNCT02572453Phase 2Results posted
• Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy ParticipantsActive, not recruitingNCT02568566Phase 2Results posted
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaActive, not recruitingNCT02567435Phase 3Results posted
• Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck CancerActive, not recruitingNCT02567422Phase 1Results posted
• Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial CancerCompletedNCT02567409Phase 2Results posted
• Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedNCT02535338Phase 1/2Results posted
• Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or CarboplatinActive, not recruitingNCT02535312Phase 1/2Results posted
• Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency AblationActive, not recruitingNCT02521285Phase 2Results posted
• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT02506153Phase 3Results posted
• Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal CancerTerminatedNCT02504892Phase 2Results posted
• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryCompletedNCT02500797Phase 2Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results posted
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedNCT02495103Phase 1/2Results posted
• Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedNCT02487979Phase 2Results posted
• Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersCompletedNCT02487095Phase 1/2Results posted
• Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaCompletedNCT02484443Phase 2Results posted

← National Cancer Institute (NCI) overview and focus areas